Clinical investigation to evaluate the capacity of LOAd703 to sensitize patients to PD-L1 therapy has recently started in a pancreatic cancer trial as well as in melanoma patients refractory to previous checkpoint inhibitor treatment (NCT02705196, NCT04123470) and in a study treating patients with refractory colorectal cancer (NCT03555149). The gene discussed is CD274; the disease is pancreatic neoplasm.